Cycle on Jul 6, 2026

I will start by listing the topic's open threads to see if there are any specific user-prioritized research questions or watches we need to resolve.

I will search the web for the latest health, science, and policy news, with a particular focus on any active watches that might have updates (e.g., Australia H5N1, FDA regulatory decisions or advisory committees, clinical trial readouts, etc.). I will use `recent: true` to get the latest week's news.

I will fetch the Sydney Morning Herald (SMH) and ABC articles regarding the growing H5N1 cases in Australia to verify if there has been transmission to poultry or local wildlife. Since the watch `Australia H5N1 transmission to poultry or local wildlife` specifically triggers on transmission to commercial poultry flocks, native land birds, or local marine mammal colonies, I need to see if the current detections are still exclusively in migratory seabirds (like petrels) or if they have officially jumped to commercial flocks or local wildlife. Let's fetch `https://www.smh.com.au/politics/federal/experts-cagey-over-free-range-chickens-as-bird-flu-cases-grow-20260706-p60czj.html` first.

I will fetch the Fierce Pharma and Applied Clinical Trials articles about the NEJM retraction of the Tavneos ADVOCATE trial paper. This is a massive update to the Tavneos topic, which links to Amgen's ongoing FDA fight. The watch `Amgen Tavneos FDA hearing submission extended deadline` has a deadline of July 29, 2026. The retraction of the pivotal paper by NEJM is a major development. Let's fetch `https://www.fiercepharma.com/pharma/medical-journal-retracts-tavneos-pivotal-study-article-complicating-amgens-defense-effort` first.

I will search for Omeros narsoplimab EMA re-examination or CHMP updates. Let's do a broader search on "Omeros" "narsoplimab" in 2026.

I will search for the press release from Omeros on June 26, 2026, about the European Marketing Authorization Application (MAA) for narsoplimab in TA-TMA. Let's run a search for this press release.

Let's fetch the Pomerantz Law Firm or Bronstein press release to see what the exact wording of Omeros's announcement on June 26, 2026, was. This will help us understand what happened to narsoplimab's MAA and if they are requesting re-examination. Let's fetch `https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-omeros-corporation---omer-302816386.html`.

I will search for the actual Omeros press release or an article detailing if they are requesting re-examination. Let's do a search on `Omeros narsoplimab CHMP negative opinion "re-examination" OR "reexamination" OR "ad hoc"`.

Let's do a broader search with `Omeros narsoplimab CHMP negative opinion "June 2026"`.

Let's look for other major news in the life sciences space this week. We have several watches. Let's check if there are updates on: 1. Capricor deramiocel (DMD cardiomyopathy) - Cellular, Tissue, and Gene Therapies Advisory Committee meeting scheduled for July 29, 2026. This is still in the future. 2. Replimune RP1 in advanced melanoma - FDA Advisory Committee late July 2026, PDUFA August 2, 2026. 3. MoonLake sonelokimab Phase 3 IZAR-1 trial readout in PsA expected in mid-2026. Let's search for `MoonLake "sonelokimab" OR "IZAR-1" 2026`. 4. Sobi BLA resubmission for NASP. Let's search `Sobi NASP BLA 2026`. 5. Achieve Life Sciences NDA cytisinicline. Let's search `Achieve Life Sciences cytisinicline NDA 2026`. 6. GondolaBio PORT-77 PATHWAY trial. Let's search `GondolaBio PORT-77 PATHWAY 2026`. 7. Definium DT120 GAD Phase 3. Let's search `Definium DT120 2026`. Let's run a search for MoonLake and sonelokimab first.

The MoonLake VELA 52-week data in HS was reported in late June 2026, but the IZAR-1 Phase 3 PsA trial readout is still slated for mid-2026 (likely July/August). No IZAR-1 results are out yet. Let's do a search on other drugs or major science/health policy events in the last week. Let's search for: `"clinical trials" FDA 2026` or `"drug approval" FDA 2026` to see what is new. Let's run a search.

There are several very interesting pieces of news here: 1. **Unicycive Therapeutics** received a **Complete Response Letter (CRL)** from the FDA on June 30, 2026, regarding its resubmitted New Drug Application (NDA) for oxylanthanum carbonate (OLC), a drug to treat hyperphosphatemia in chronic kidney disease patients on dialysis. The CRL relates to deficiencies previously identified at a third-party manufacturing vendor. 2. **Ascelia Pharma** received a **CRL** for **Orviglance** (manganese dipyridoxyl diphosphate) NDA. Let's research this CRL. 3. **Pharvaris**' NDA for deucrictibant immediate-release (IR) capsules was accepted by the FDA for hereditary angioedema (HAE) attacks. 4. **Organogenesis** announced FDA acceptance of its BLA for ReNu (knee osteoarthritis treatment). 5. **Summit Therapeutics** - FDA acceptance of the ivonescimab BLA (which relates to our ongoing watch `Global Phase 3 trial readouts for ivonescimab (HARMONi studies)` and Summit's development of ivonescimab). Let's search for this BLA acceptance! Let's look into **Unicycive Therapeutics' CRL**. I will search for more details.

Let's fetch `https://www.globenewswire.com/news-release/2026/06/30/3319541/0/en/unicycive-therapeutics-receives-complete-response-letter-from-fda-regarding-resubmitted-oxylanthanum-carbonate-olc-new-drug-application-nda.html` to understand Unicycive's CRL details. This is a significant drug approval/regulatory event.

I will now draft the findings using the information obtained from this cycle's research. First, let's address the major update for **Tavneos (avacopan)**: - **Slug**: `amgen-tavneos-fda-hearing-nejm-retraction` (or since we have a watch title `Amgen Tavneos FDA hearing submission extended deadline`, we can write a note explaining this critical update). Let's write a note focusing on the NEJM retraction of the pivotal trial paper and the escalating pressure from regulators on both sides of the Atlantic. Second, let's address the **Australia H5N1** situation: - **Slug**: `australia-h5n1-avian-influenza-seabirds` - We have an ongoing watch: `Australia H5N1 transmission to poultry or local wildlife` (id: `019f2f50-7f4d-7361-8f05-cdf170c2d727`). - The evidence confirms that as of July 6, 2026, there are now **seven** confirmed infected wild seabirds (the latest being a giant petrel in Perth, WA, and others on the NSW Mid North Coast), but **no sign** of transmission to farmed poultry or local wildlife. Since the watch triggers on transmission to commercial poultry flocks, native land birds, or local marine mammal colonies, it has **not** fired yet, but the threat is growing and biosecurity measures are ramping up (e.g., advising free-range poultry farmers to move birds indoors). Third, let's address **Omeros Corporation's narsoplimab**: - **Slug**: `omeros-narsoplimab-chmp-negative-opinion-ta-tma` - On June 26, 2026, the EMA's CHMP adopted a negative opinion on the MAA for narsoplimab in TA-TMA. This is a direct update on the watch `EMA re-examination outcome on Omeros's narsoplimab in TA-TMA`. Fourth, let's address **Unicycive Therapeutics' oxylanthanum carbonate (OLC)**: - **Slug**: `unicycive-therapeutics-oxylanthanum-carbonate-crl` - On June 30, 2026, Unicycive received a second CRL from the FDA for OLC, solely due to unresolved third-party manufacturing vendor deficiencies, with no safety/efficacy concerns raised. Let's write these notes. I will construct the first note on the Tavneos NEJM retraction.

I will now write a note on Omeros Corporation's narsoplimab receiving a negative CHMP opinion. This directly addresses the thread/watch `EMA re-examination outcome on Omeros's narsoplimab in TA-TMA`. I will write a note under the slug `omeros-narsoplimab-chmp-negative-opinion-ta-tma`.

I will now write a note on Unicycive Therapeutics' second Complete Response Letter (CRL) from the FDA for its kidney disease drug oxylanthanum carbonate (OLC). This is a major regulatory update in the dialysis space. I will use the slug `unicycive-therapeutics-oxylanthanum-carbonate-crl`.

I will now write a note on the Australian H5N1 situation. This addresses the active watch `Australia H5N1 transmission to poultry or local wildlife`. The current evidence shows that cases in wild migratory birds are growing (now up to 7 cases, reaching the East Coast in NSW and Perth on the west coast), but transmission to commercial flocks or local endemic wildlife has NOT occurred yet. I will use the slug `australia-h5n1-avian-influenza-seabirds`.

I will record events on the watches that have had major developments. 1. The watch `EMA re-examination outcome on Omeros's narsoplimab in TA-TMA` (id: `019f0620-0add-7ac7-9db1-1ce428418522`) is a one-shot watch. The CHMP has adopted a negative opinion. Omeros is requesting re-examination. The watch is ongoing in terms of the final decision, but since this is a negative opinion and they are requesting re-examination, let's record an event on it. Let's see if we should resolve it or keep it open. Since the watch description says "Monitor Omeros's request for re-examination... and the final decision", and they are just initiating the request now after the negative opinion, let's record an event with `resolves: false` to keep tracking.

Now let's check if we should resolve any other threads or record any other watches. Let's look at the watch `Australia H5N1 transmission to poultry or local wildlife` (id: `019f2f50-7f4d-7361-8f05-cdf170c2d727`). We can record an event showing that cases in wild seabirds have increased to seven, but no transmission to poultry or local wildlife has been confirmed yet. This is an ongoing watch, so `resolves: false`.

I will now call `finish_cycle` to complete this research cycle, as we have successfully written the findings and recorded events for our active watches.

I have completed the research cycle for this topic. Here is a summary of the key findings and updates: 1. **Amgen's Tavneos Pivotal Trial Retraction**: *The New England Journal of Medicine* (NEJM) retracted the pivotal 2021 ADVOCATE trial paper for Tavneos (avacopan). The retraction follows an FDA investigation finding that primary endpoint data for nine patients was readjudicated after database lock and unblinding without the authors' knowledge. This significantly complicates Amgen's defense ahead of its July 29, 2026, deadline to submit independent DCRI re-adjudication data and request a formal FDA hearing to keep the drug on the US market. 2. **Omeros's Narsoplimab Negative CHMP Opinion**: The EMA's CHMP adopted a negative opinion on Omeros's Marketing Authorization Application (MAA) for narsoplimab in TA-TMA. Omeros plans to request a formal re-examination and seek an independent Ad Hoc Expert Group (AHEG) review, but the near-term European commercial path is now clouded. 3. **Unicycive's Second FDA CRL**: Unicycive Therapeutics received a second Complete Response Letter (CRL) from the FDA for its kidney disease drug oxylanthanum carbonate (OLC). The FDA raised no safety or efficacy concerns; the rejection is entirely due to unresolved deficiencies at a third-party manufacturing vendor which the FDA has yet to re-inspect. 4. **Australia H5N1 Update**: Confirmed cases of H5N1 in wild migratory seabirds have risen to seven, spreading to both the East Coast (NSW) and Western Australia. While biosecurity alerts are escalating—with veterinary officers recommending that free-range poultry farmers move their flocks indoors—no transmission to commercial poultry or local endemic wildlife has yet occurred.